108 related articles for article (PubMed ID: 89330)
1. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.
Bergquist C; Nillius SJ; Wide L
Lancet; 1979 Aug; 2(8136):215-7. PubMed ID: 89330
[TBL] [Abstract][Full Text] [Related]
2. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
Nillius SJ; Bergquist C; Wide L
Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
[TBL] [Abstract][Full Text] [Related]
4. Chronic effects of the stimulatory luteinizing hormone-releasing hormone analogue D-Ser (TBU) 6-EA 10-LRH on the gonadotrophin and gonadal steroid secretion in women with amenorrhoea.
Skarin G; Nillius SJ; Wide L
Ups J Med Sci; 1980; 85(2):103-12. PubMed ID: 6787767
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue - a new approach to birth control?
Nillius SJ; Bergquist C; Wide L
Contraception; 1978 Jun; 17(6):537-44. PubMed ID: 363344
[TBL] [Abstract][Full Text] [Related]
6. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
Bergquist C; Nillius SJ; Wide L; Lindgren A
Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.
Bergquist C; Nillius SJ; Wide L
Contraception; 1979 May; 19(5):497-506. PubMed ID: 380892
[TBL] [Abstract][Full Text] [Related]
8. Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects.
Bergquist C; Nillius SJ; Wide L
Clin Endocrinol (Oxf); 1982 Jul; 17(1):91-8. PubMed ID: 6811167
[TBL] [Abstract][Full Text] [Related]
9. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
10. Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women.
Bergquist C; Nillius SJ; Wide L
Contraception; 1980 Sep; 22(3):287-93. PubMed ID: 7002443
[TBL] [Abstract][Full Text] [Related]
11. Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.
Skarin G; Nillius SJ; Wide L
Contraception; 1982 Jan; 25(1):31-9. PubMed ID: 6800690
[TBL] [Abstract][Full Text] [Related]
12. Failure of positive feedback of oestradiol during chronic intranasal luteinizing hormone-releasing hormone agonist treatment.
Bergquist C; Nillius SJ; Wide L
Clin Endocrinol (Oxf); 1982 Feb; 16(2):147-51. PubMed ID: 6802530
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.
Nillius SJ
J Steroid Biochem; 1985 Nov; 23(5B):849-54. PubMed ID: 2934581
[TBL] [Abstract][Full Text] [Related]
14. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
Gudmundsson JA; Nillius SJ; Bergquist C
Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
[TBL] [Abstract][Full Text] [Related]
15. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; von der Ohe M; Nevinny-Stickel J
Contraception; 1981 Feb; 23(2):187-95. PubMed ID: 6786826
[TBL] [Abstract][Full Text] [Related]
16. Reduced gonadotropin secretion in postmenopausal women during treatment with a stimulatory LRH analogue.
Bergquist C; Nillius SJ; Wide L
J Clin Endocrinol Metab; 1979 Sep; 49(3):472-4. PubMed ID: 381324
[TBL] [Abstract][Full Text] [Related]
17. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
18. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
Gudmundsson JA; Nillius SJ; Bergquist C
Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
[TBL] [Abstract][Full Text] [Related]
20. Effects of prolonged luteinizing hormone-releasing hormone therapy on follicular maturation, ovulation and corpus luteum function in amenorrhoeic women with anorexia nervosa.
Nillius SJ; Wide L
Ups J Med Sci; 1979; 84(1):21-35. PubMed ID: 375526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
